Literature DB >> 8210304

Management of paroxysmal atrial fibrillation.

G Y Lip1, M J Metcalfe, A P Rae.   

Abstract

Paroxysmal atrial fibrillation is a common, poorly understood and difficult-to-treat arrhythmia. Although it tends to be treated in a similar fashion to chronic atrial fibrillation, its pathophysiology is different, and drugs commonly used for chronic atrial fibrillation may have only limited value in treating paroxysmal atrial fibrillation. A broad range of presenting clinical symptoms may be associated with this arrhythmia, and even in the asymptomatic patient, there may be a risk of serious thromboembolic events. In symptomatic patients, effective control of paroxysms with antiarrhythmic therapy can often be difficult, and the role of anticoagulation remains controversial. This review attempts to clarify these issues, by surveying the range of therapies available.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8210304     DOI: 10.1093/qjmed/86.8.467

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  8 in total

1.  Polypharmacotherapy and blood products as risk factors for venous thromboembolism in postsurgical patients: a case-control study.

Authors:  Alenka Premuš Marušič; Daniel Petrovič; Aleš Mrhar; Igor Locatelli
Journal:  Int J Clin Pharm       Date:  2017-03-09

2.  A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project.

Authors:  G Y Lip; D J Golding; M Nazir; D G Beevers; D L Child; R I Fletcher
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

Review 3.  ABC of atrial fibrillation. Drugs for atrial fibrillation.

Authors:  G Y Lip; R D Watson; S P Singh
Journal:  BMJ       Date:  1995-12-16

4.  An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.

Authors:  R P Steeds; A S Birchall; M Smith; K S Channer
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

Review 5.  Fetal cardiomyocyte phenotype, ketone body metabolism, and mitochondrial dysfunction in the pathology of atrial fibrillation.

Authors:  Sean M Brown; Nicholas K Larsen; Finosh G Thankam; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2020-11-13       Impact factor: 3.396

6.  Inflammation as a risk factor for stroke in atrial fibrillation: data from a microarray data analysis.

Authors:  Yingyuan Li; Wulin Tan; Fang Ye; Shihong Wen; Rong Hu; Xiaoying Cai; Kebing Wang; Zhongxing Wang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

7.  Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.

Authors:  Ching-Yu Wang; Phuong N Pham; Sarah Kim; Karthik Lingineni; Stephan Schmidt; Vakaramoko Diaby; Joshua Brown
Journal:  Clin Transl Sci       Date:  2020-02-13       Impact factor: 4.689

8.  Comparison between surgical and catheter based ablation in atrial fibrillation, should surgical based ablation be implemented as first line? - A meta-analysis of studies.

Authors:  Emir Yonas; Raymond Pranata; Bambang Budi Siswanto; Hafil Budianto Abdulgani
Journal:  Indian Pacing Electrophysiol J       Date:  2019-12-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.